Clinical Trials

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT02031250 2026-03-02

Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer

106 enrolled 12 charts

Phase 3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT02453282 2026-03-02

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Phase 2 Active not recruiting

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

39 enrolled 8 charts

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00003042 2026-02-20

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

41 enrolled 9 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03366766 2026-02-20

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04221945 2026-02-20

KEYNOTE-A18

1,060 enrolled 30 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03143153 2026-02-17

CheckMate 648

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT03822897 2026-02-17

EVADER

Phase 2 Active not recruiting

103 enrolled 11 charts

Phase 1/2 Active not recruiting

Oropharyngeal Neoplasms

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

24 enrolled 59 charts

Ovarian Cancer Recurrent

NCT05577702 2026-02-09

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

121 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT04809103 2026-02-06

Intratumoral Cisplatin for Resectable NSCLC

Phase 1 Completed

6 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung

NCT03829319 2026-02-05

LEAP-006

761 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05226598 2026-02-05

MK-7684A-007

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03040999 2026-02-04

KEYNOTE-412

804 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04648033 2026-01-29

ARCADIAN

Phase 1 Completed

21 enrolled 21 charts

Phase 3 Active not recruiting

Locally Advanced Non-Small Cell Lung Cancer

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Genitourinary

Urothelial Cancer

NCT02690558 2026-01-28

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Active not recruiting

39 enrolled 16 charts

Genitourinary

Urinary Bladder Neoplasms

NCT00336024 2026-01-23

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

91 enrolled 24 charts

CNS

Medulloblastoma

NCT01175356 2026-01-23

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Phase 1 Completed

99 enrolled 11 charts

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT01302834 2026-01-12

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Head & NeckOther neoplasm

987 enrolled 59 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Precancerous Conditions, Papillomavirus Infections

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT00980954 2025-12-31

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

236 enrolled 28 charts

Uterine Cervical Neoplasms

NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1/2 Terminated

75 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT02611037 2025-12-18

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Other solid neoplasmThoracic

34 enrolled 12 charts

Mesothelioma, Malignant, Mesothelioma

NCT03215706 2025-12-17

CheckMate 9LA

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

89 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03132532 2025-11-25

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

20 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts